Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 11/20 | 0.53 |
| ▸ | DKK1 | O94907 | 2/20 | 0.53 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | CDK2 | P24941 | 4/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.52 |
| ▸ | CDK1 | P06493 | 4/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.52 |
| ▸ | CDK9 | P50750 | 4/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK7 | P50613 | 1/20 | 0.47 |
| ▸ | CCNH | P51946 | 1/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2541549 | 0.93 | CDK2 (0.53) | IKBKBDKK1GSK3BCDK2CCNT1 | |
| SCHEMBL2545759 | 0.89 | CDK1 (0.55) | IKBKBCDK2CCNT1CDK1CCNB1 | |
| SCHEMBL2540573 | 0.82 | CDK1 (0.56) | IKBKBCDK2CCNT1CDK1CCNB1 | |
| SCHEMBL2540451 | 0.82 | IKBKB (0.53) | IKBKBDKK1GSK3BCDK2CCNT1 | |
| SCHEMBL2538339 | 0.81 | CCNT1 (0.49) | IKBKBDKK1GSK3BCDK2CCNT1 | |
| SCHEMBL2545739 | 0.80 | CCNT1 (0.57) | IKBKBDKK1GSK3BCDK2CCNT1 | |
| SCHEMBL2544929 | 0.79 | CCNT1 (0.58) | IKBKBDKK1GSK3BCDK2CCNT1 | |
| SCHEMBL2538150 | 0.79 | ACVR1 (0.56) | CDK2CCNT1CDK1CCNB1CDK9 | |
| SCHEMBL2539360 | 0.78 | IKBKB (0.59) | IKBKBCDK2 | |
| SCHEMBL2546324 | 0.77 | BTK (0.54) | CDK2CCNT1CDK1CCNB1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | LUO YING (CN) | 2014-10-09 | — | — | US | claimed |
| US-8309550-B2 | Kinase inhibitors and their use as pharmaceutical agents | SHANGHAI GENOMICS, INC. (CN) | 2012-11-13 | — | — | US | claimed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | claimed |
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | LUO YING (CN) | 2014-10-09 | — | — | US | disclosed |
| US-8309550-B2 | Kinase inhibitors and their use as pharmaceutical agents | SHANGHAI GENOMICS, INC. (CN) | 2012-11-13 | — | — | US | disclosed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | MAP3K20, MAP3K1, MAP3K2 | IKBKB 348/4885DKK1 1897/4885GSK3B 329/4885 |
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | NFKBIA, IRAK1, IRAK3 | IKBKB 50/4885DKK1 2708/4885GSK3B 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.